DDInter178 DDInter1626
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185]
Rucaparib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Rucaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilonacept
Rucaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Rucaparib {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Rucaparib {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Rucaparib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Rucaparib may lead to a major life threatening interaction when taken with Baricitinib
Rucaparib may lead to a major life threatening interaction when taken with Berotralstat